Special Lecture
Glucocorticoids and the osteoclast
S.L. Teitelbaum1
- Washington University School of Medicine, St. Louis Missouri, USA. teitelbs@wustl.edu
CER8936
2015 Vol.33, N°4 ,Suppl.92
PI 0037, PF 0039
Special Lecture
Free to view
(click on article PDF icon to read the article)
PMID: 26458014 [PubMed]
Received: 03/09/2015
Accepted : 03/09/2015
In Press: 12/10/2015
Published: 14/10/2015
Abstract
Glucocorticoid-induced osteoporosis uniformly represents suppression of bone formation. The steroid’s effects on osteoclasts are, however, controversial. While glucocorticoid administration to patients with inflammatory diseases accelerates bone resorption, osteoclast function falls below normal with prolonged treatment. Thus, administration of anti-resorptive agents, such as bisphosphonates, is justified during early glucocorticoid therapy, but further suppression of osteoclasts, by these drugs, in chronically treated patients will dampen bone remodelling and may compromise skeletal quality, predisposing to fracture.
